<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL-1 and BL-E External request</td>
<td>Submission from Pacific Edge Diagnostics for BL-1: include the Cxbladder assays as a component of the Initial Evaluation. Specifically, below the bullet &quot;Consider cytology&quot;, add a new bullet with &quot;Consider Cxbladder. For BL-E: include the Cxbladder assays in the list corresponding to &quot;Urine Tests - Consider urinary urothelial tumor markers&quot;. Specifically, on MS-10 Surveillance replace &quot;Consideration may be given to FDA-approved urinary biomarker testing by fluorescence in situ hybridization {FISH) or nuclear matrix protein 22 in monitoring for recurrence&quot; with &quot;Consideration may be given to urinary biomarker testing by fluorescence in situ hybridization (FISH), nuclear matrix protein 22, or Cxbladder mRNA gene expression in monitoring for recurrence&quot;.</td>
<td>YES NO ABSTAIN ABSENT</td>
</tr>
<tr>
<td></td>
<td>• Based on discussion, the panel consensus was to not include “Cxbladder assays” due to its limited use and available data. o See Submission for references.</td>
<td>0 15 0 12</td>
</tr>
<tr>
<td>BL-4 Internal request</td>
<td>Institutional review comment to consider to include intravesical therapy as an option for non-cystectomy candidates with cT2 disease treated with TURBT alone.</td>
<td>Based on discussion, the panel consensus was to include &quot;consider intravesical BCG&quot; as an option for non-cystectomy candidates with cT2 disease treated with TURBT alone. In addition, for adjuvant treatment after no tumor, &quot;if prior BCG, maintenance BCG&quot; was added.</td>
</tr>
</tbody>
</table>